Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

377 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.
Geyer CE Jr, Untch M, Huang CS, Mano MS, Mamounas EP, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, D'Hondt V, Conlin AK, Guarneri V, Wapnir IL, Jackisch C, Arce-Salinas C, Fasching PA, DiGiovanna MP, Crown JP, Wuelfing P, Shao Z, Rota Caremoli E, Bonnefoi HR, Hennessy BT, Stamatovic L, Castro-Salguero H, Brufsky AM, Knott A, Siddiqui A, Lambertini C, Boulet T, Nyawira B, Restuccia E, Loibl S; KATHERINE Study Group. Geyer CE Jr, et al. Among authors: wolmark n. N Engl J Med. 2025 Jan 16;392(3):249-257. doi: 10.1056/NEJMoa2406070. N Engl J Med. 2025. PMID: 39813643 Clinical Trial.
Correlative Science in the Cooperative Group System: Re-Engineering for Success.
O'Dwyer PJ, Wolmark N, Hawkins DS, Schnall M, Dancey J, Blanke C, Mannel R, Galanis E, Le QT. O'Dwyer PJ, et al. Among authors: wolmark n. J Clin Oncol. 2024 Nov 20;42(33):3905-3910. doi: 10.1200/JCO.24.00527. Epub 2024 Sep 17. J Clin Oncol. 2024. PMID: 39288338 No abstract available.
Quality-of-life outcomes from NRG Oncology NSABP B-39/RTOG 0413: whole-breast irradiation vs accelerated partial-breast irradiation after breast-conserving surgery.
Ganz PA, Cecchini RS, White JR, Vicini FA, Arthur DW, Rabinovitch RA, Kuske RR, Julian TB, Parda DS, Scheier MF, Winter KA, Paik S, Kuerer HM, Vallow LA, Pierce LJ, Mamounas EP, McCormick B, Bear HD, Germain I, Gustafson GS, Grossheim L, Petersen IA, Hudes RS, Curran WJ Jr, Wolmark N. Ganz PA, et al. Among authors: wolmark n. J Natl Cancer Inst. 2025 Jan 1;117(1):103-111. doi: 10.1093/jnci/djae219. J Natl Cancer Inst. 2025. PMID: 39254630 Clinical Trial.
Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis.
Chibaudel B, Raeisi M, Cohen R, Yothers G, Goldberg RM, Bachet JB, Wolmark N, Yoshino T, Schmoll HJ, Kerr R, Lonardi S, George TJ, Shacham-Shmueli E, Shi Q, André T, de Gramont A. Chibaudel B, et al. Among authors: wolmark n. J Clin Oncol. 2024 Dec 10;42(35):4187-4195. doi: 10.1200/JCO.24.00394. Epub 2024 Sep 4. J Clin Oncol. 2024. PMID: 39231393
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial.
Rastogi P, Bandos H, Lucas PC, van 't Veer LJ, Wei JJ, Geyer CE Jr, Fehrenbacher L, Chia SKL, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Paik S, Swain SM, Menicucci AR, Audeh MW, Wolmark N, Mamounas EP. Rastogi P, et al. Among authors: wolmark n. J Clin Oncol. 2024 Oct 20;42(30):3561-3569. doi: 10.1200/JCO.23.01995. Epub 2024 Jul 24. J Clin Oncol. 2024. PMID: 39047219 Free PMC article. Clinical Trial.
Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival.
Sparano JA, Crager M, Gray RJ, Tang G, Hoag J, Baehner FL, Shak S, Makower DF, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Whelan TJ, Kaklamani VG, Wolmark N, Sledge GW, Stemmer SM. Sparano JA, et al. Among authors: wolmark n. NEJM Evid. 2024 Aug;3(8):EVIDoa2300267. doi: 10.1056/EVIDoa2300267. Epub 2024 Jul 23. NEJM Evid. 2024. PMID: 39041867
Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Jacobs SA, Wang Y, Abraham J, Feng H, Montero AJ, Lipchik C, Finnigan M, Jankowitz RC, Salkeni MA, Maley SK, Puhalla SL, Piette F, Quinn K, Chang K, Nagy RJ, Allegra CJ, Vehec K, Wolmark N, Lucas PC, Srinivasan A, Pogue-Geile KL. Jacobs SA, et al. Among authors: wolmark n. Breast Cancer Res. 2024 May 24;26(1):83. doi: 10.1186/s13058-024-01833-6. Breast Cancer Res. 2024. PMID: 38790033 Free PMC article. No abstract available.
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Jacobs SA, Wang Y, Abraham J, Feng H, Montero AJ, Lipchik C, Finnigan M, Jankowitz RC, Salkeni MA, Maley SK, Puhalla SL, Piette F, Quinn K, Chang K, Nagy RJ, Allegra CJ, Vehec K, Wolmark N, Lucas PC, Srinivasan A, Pogue-Geile KL. Jacobs SA, et al. Among authors: wolmark n. Breast Cancer Res. 2024 Apr 22;26(1):69. doi: 10.1186/s13058-024-01823-8. Breast Cancer Res. 2024. PMID: 38650031 Free PMC article. Clinical Trial.
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial.
Mamounas EP, Bandos H, Rastogi P, Zhang Y, Treuner K, Lucas PC, Geyer CE Jr, Fehrenbacher L, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil S, Paik S, Swain SM, Sgroi DC, Schnabel CA, Wolmark N. Mamounas EP, et al. Among authors: wolmark n. Clin Cancer Res. 2024 May 1;30(9):1984-1991. doi: 10.1158/1078-0432.CCR-23-1977. Clin Cancer Res. 2024. PMID: 38376912 Free PMC article. Clinical Trial.
377 results